Trials / Not Yet Recruiting
Not Yet RecruitingNCT07329556
Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases
Evaluation of Advanced Glycation End Products Accumulation in Rheumatic Diseases Using Non-Invasive Skin Autofluorescence Measurements
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Bursa City Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Rheumatic diseases are chronic inflammatory conditions that can lead to long-term tissue damage and increased cardiovascular and metabolic risk. Advanced glycation end products (AGEs) are harmful molecules that accumulate in the body over time and are known to promote inflammation and oxidative stress. Increased AGE burden has been implicated in several chronic diseases; however, its role in rheumatic diseases has not been fully clarified. This observational, cross-sectional study aims to evaluate the accumulation of AGEs in patients with various rheumatic diseases compared with healthy individuals. AGE levels will be assessed non-invasively using skin autofluorescence measurements. By comparing AGE burden between patients and healthy controls, this study seeks to improve understanding of the potential role of AGEs in the pathophysiology of rheumatic diseases and to explore their usefulness as a non-invasive biomarker in clinical practice.
Conditions
- Rheumatoid Arthritis (RA
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Reactive Arthritis (ReA)
- Crystal Arthropathies
- Connective Tissue Diseases
- Familial Mediterranean Fever (FMF )
Timeline
- Start date
- 2026-01-15
- Primary completion
- 2027-01-15
- Completion
- 2027-04-15
- First posted
- 2026-01-09
- Last updated
- 2026-01-09
Source: ClinicalTrials.gov record NCT07329556. Inclusion in this directory is not an endorsement.